, but a study shows the risk of certain clots is higher in those who get Covid. A new study has revealed that people who get Covid-19 are more likely to get certain types of . The research published as a pre-print in The Lancet examined the medical records of about six million people in Spain, including with AstraZeneca and approximately 900,000 who got at least one dose of Pfizer.
It found higher rates of thromboembolism and thrombocytopenia — blood clots that can cause stroke or heart attacks — among those who got sick with the coronavirus than those vaccinated. In particular, the venous thromboembolism (VTE) rate increased by eight . In comparison, those who got one only saw the risk increase by 1.3 times. AstraZeneca’s risk was very similar, rising by 1.1 . “For each of the , rates of thrombosis can be expected to be far lower than COVID-19, a disease which the vaccines are so effective at preventing,” the paper states.
is the only way for Australians to get their everyday lives back, but as a nation, we’re struggling. It’s fair to rollout has confused Australians. We’ll cut through the spin and give you clear information so you can make an informed decision. Unfortunately, the research doesn’t provide much insight into thrombosis with thrombocytopenia syndrome (TTS), the . physician and microbiologist Associate Professor Paul Griffin of the University of Queensland said more research was needed to understand the rate of TTS because the diagnostic criteria for identifying TTS were not necessarily met by the cases in the study.
“You’re not necessarily comparing like with like,” he said, news.com.au. TTS more commonly causes large abdominal clots, unlike venous thromboembolism (VTE) and arterial thromboembolism (ATE), which cause stroke and heart attacks. Prof Griffinaround blood clot deaths around AstraZeneca but did show that you were more likely to get other types of blood clots, which could also lead to death if you got Covid-19. “The most important conclusion, which we sort of knew already, is that of venous thromboembolism (VTE) and arterial thromboembolism (ATE),” he said.
He had fairly similar rates regarding the risk of VTE and ATE, AstraZeneca, and Pfizer. Still, Prof Griffin noted that the number of people who got AZ in the study was significantly less than those who got Pfizer, so there is uncertainty around the significance of this figure. While the study didn’t shed more light on TTS, Prof Griffin said communication around the risks and benefits of AstraZeneca needed to improve. “We have overemphasized the risks but not the benefits,” he said. “Covid will , and the significant but exceedingly rare consequence (of AZ) has led to a lot of concern about vaccination that is a bit misplaced. “Every vaccination, every medical therapy has potential , but I think we haven’t communicated that in a balanced way,”